Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment. The post Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug appeared first on Investor's Business Daily.
Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.
The post Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
